Most Ligand-Based Benchmarks Measure Overfitting Rather than Accuracy
暂无分享,去创建一个
[1] Zhenming Liu,et al. An Unbiased Method To Build Benchmarking Sets for Ligand-Based Virtual Screening and its Application To GPCRs , 2014, J. Chem. Inf. Model..
[2] Paul Watson,et al. Virtual Screening Using Protein-Ligand Docking: Avoiding Artificial Enrichment , 2004, J. Chem. Inf. Model..
[3] Peer Bork,et al. The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..
[4] Vijay S. Pande,et al. Molecular graph convolutions: moving beyond fingerprints , 2016, Journal of Computer-Aided Molecular Design.
[5] Fionn Murtagh,et al. Algorithms for hierarchical clustering: an overview , 2012, WIREs Data Mining Knowl. Discov..
[6] R. Venkataraghavan,et al. Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..
[7] Jürgen Bajorath,et al. MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..
[8] Eric Jones,et al. SciPy: Open Source Scientific Tools for Python , 2001 .
[9] Ajay N. Jain. Bias, reporting, and sharing: computational evaluations of docking methods , 2008, J. Comput. Aided Mol. Des..
[10] Hiroaki Wakabayashi,et al. Predicting Key Example Compounds in Competitors' Patent Applications Using Structural Information Alone , 2008, J. Chem. Inf. Model..
[11] Robert P. Sheridan,et al. Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships , 2015, J. Chem. Inf. Model..
[12] Ajay N. Jain,et al. Effects of inductive bias on computational evaluations of ligand-based modeling and on drug discovery , 2008, J. Comput. Aided Mol. Des..
[13] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[14] Robert P. Sheridan,et al. Chemical Similarity Using Physiochemical Property Descriptors , 1996, J. Chem. Inf. Comput. Sci..
[15] Geoffrey E. Hinton,et al. Visualizing Data using t-SNE , 2008 .
[16] Heike Schönherr,et al. Profound methyl effects in drug discovery and a call for new C-H methylation reactions. , 2013, Angewandte Chemie.
[17] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[18] James G. Nourse,et al. Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..
[19] Roger A. Sayle,et al. Electrostatic evaluation of isosteric analogues , 2006, J. Comput. Aided Mol. Des..
[20] Anne Mai Wassermann,et al. REPROVIS-DB: A Benchmark System for Ligand-Based Virtual Screening Derived from Reproducible Prospective Applications , 2011, J. Chem. Inf. Model..
[21] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[22] Tudor I. Oprea,et al. Optimization of CAMD techniques 3. Virtual screening enrichment studies: a help or hindrance in tool selection? , 2008, J. Comput. Aided Mol. Des..
[23] Yann LeCun,et al. The mnist database of handwritten digits , 2005 .
[24] Jean-Louis Reymond,et al. Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17 , 2012, J. Chem. Inf. Model..
[25] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[26] Steven K. Gibb. Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.
[27] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[28] Sebastian G. Rohrer,et al. Maximum Unbiased Validation (MUV) Data Sets for Virtual Screening Based on PubChem Bioactivity Data , 2009, J. Chem. Inf. Model..
[29] Steven J Brown,et al. A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells , 2015, Cell.
[30] Paul Covington,et al. Deep Neural Networks for YouTube Recommendations , 2016, RecSys.
[31] A. Vulpetti,et al. The experimental uncertainty of heterogeneous public K(i) data. , 2012, Journal of medicinal chemistry.
[32] Vijay S. Pande,et al. Massively Multitask Networks for Drug Discovery , 2015, ArXiv.
[33] Vijay S. Pande,et al. MoleculeNet: a benchmark for molecular machine learning , 2017, Chemical science.
[34] A. Vulpetti,et al. Comparability of Mixed IC50 Data – A Statistical Analysis , 2013, PloS one.
[35] Eric J. Martin,et al. Profile-QSAR 2.0: Kinase Virtual Screening Accuracy Comparable to Four-Concentration IC50s for Realistically Novel Compounds , 2017, J. Chem. Inf. Model..
[36] Jürgen Bajorath,et al. Systematic Identification and Classification of Three-Dimensional Activity Cliffs , 2012, J. Chem. Inf. Model..
[37] Brian Goldman,et al. Modeling Industrial ADMET Data with Multitask Networks , 2016, 1606.08793.
[38] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[39] Ajay N. Jain,et al. Does your model weigh the same as a Duck? , 2011, Journal of Computer-Aided Molecular Design.
[40] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[41] Ajay N. Jain,et al. Chemical structural novelty: on-targets and off-targets. , 2011, Journal of medicinal chemistry.
[42] Andreas Mayr,et al. Deep Learning as an Opportunity in Virtual Screening , 2015 .